vs
Side-by-side financial comparison of Cardiff Oncology, Inc. (CRDF) and Pluri Inc. (PLUR). Click either name above to swap in a different company.
Pluri Inc. is the larger business by last-quarter revenue ($398.0K vs $243.0K, roughly 1.6× Cardiff Oncology, Inc.). On growth, Pluri Inc. posted the faster year-over-year revenue change (314.6% vs 62.0%). Over the past eight quarters, Pluri Inc.'s revenue compounded faster (171.5% CAGR vs 8.9%).
Pluri Inc., formerly Pluristem Therapeutics, is an Israeli company engaged in the development of human placental adherent stromal cells for commercial use in disease treatment. According to the company's website, it extracts adult stem cells exclusively from postnatal placentas.
CRDF vs PLUR — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $243.0K | $398.0K |
| Net Profit | $-7.2M | — |
| Gross Margin | — | 52.0% |
| Operating Margin | -3221.0% | — |
| Net Margin | -2969.5% | — |
| Revenue YoY | 62.0% | 314.6% |
| Net Profit YoY | 38.8% | -32.6% |
| EPS (diluted) | $-0.11 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $243.0K | — | ||
| Q3 25 | $120.0K | — | ||
| Q2 25 | $121.0K | $398.0K | ||
| Q1 25 | $109.0K | $427.0K | ||
| Q4 24 | $150.0K | $185.0K | ||
| Q3 24 | $165.0K | $326.0K | ||
| Q2 24 | $163.0K | $96.0K | ||
| Q1 24 | $205.0K | $71.0K |
| Q4 25 | $-7.2M | — | ||
| Q3 25 | $-11.3M | — | ||
| Q2 25 | $-13.9M | — | ||
| Q1 25 | $-13.4M | $-6.1M | ||
| Q4 24 | $-11.8M | $-3.0M | ||
| Q3 24 | $-11.9M | $-5.9M | ||
| Q2 24 | $-11.8M | — | ||
| Q1 24 | $-10.0M | $-5.3M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 52.0% | ||
| Q1 25 | — | 31.9% | ||
| Q4 24 | — | 60.0% | ||
| Q3 24 | — | 61.3% | ||
| Q2 24 | — | 95.8% | ||
| Q1 24 | — | 100.0% |
| Q4 25 | -3221.0% | — | ||
| Q3 25 | -9978.3% | — | ||
| Q2 25 | -12212.4% | — | ||
| Q1 25 | -13194.5% | -1264.6% | ||
| Q4 24 | -8381.3% | -2679.5% | ||
| Q3 24 | -7637.0% | -1594.5% | ||
| Q2 24 | -7696.3% | — | ||
| Q1 24 | -5333.2% | -7794.4% |
| Q4 25 | -2969.5% | — | ||
| Q3 25 | -9381.7% | — | ||
| Q2 25 | -11523.1% | — | ||
| Q1 25 | -12324.8% | -1439.6% | ||
| Q4 24 | -7858.0% | -1597.8% | ||
| Q3 24 | -7184.8% | -1804.3% | ||
| Q2 24 | -7225.8% | — | ||
| Q1 24 | -4883.4% | -7454.9% |
| Q4 25 | $-0.11 | — | ||
| Q3 25 | $-0.17 | — | ||
| Q2 25 | $-0.21 | — | ||
| Q1 25 | $-0.20 | $-0.94 | ||
| Q4 24 | $-0.22 | $-0.53 | ||
| Q3 24 | $-0.25 | $-1.08 | ||
| Q2 24 | $-0.26 | — | ||
| Q1 24 | $-0.22 | $-1.01 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $58.3M | $5.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $45.4M | $-6.8M |
| Total Assets | $61.9M | $38.7M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $58.3M | — | ||
| Q3 25 | $60.6M | — | ||
| Q2 25 | $71.0M | $5.9M | ||
| Q1 25 | $79.9M | $8.5M | ||
| Q4 24 | $91.7M | $7.2M | ||
| Q3 24 | $57.7M | $3.2M | ||
| Q2 24 | $60.3M | $6.8M | ||
| Q1 24 | $67.2M | $7.1M |
| Q4 25 | $45.4M | — | ||
| Q3 25 | $48.8M | — | ||
| Q2 25 | $58.6M | $-6.8M | ||
| Q1 25 | $70.9M | $-4.5M | ||
| Q4 24 | $82.9M | $-8.0M | ||
| Q3 24 | $49.4M | $-5.3M | ||
| Q2 24 | $52.4M | $96.0K | ||
| Q1 24 | $60.9M | $-356.0K |
| Q4 25 | $61.9M | — | ||
| Q3 25 | $63.8M | — | ||
| Q2 25 | $75.7M | $38.7M | ||
| Q1 25 | $84.8M | $37.4M | ||
| Q4 24 | $97.2M | $30.9M | ||
| Q3 24 | $62.9M | $35.4M | ||
| Q2 24 | $66.1M | $39.5M | ||
| Q1 24 | $74.0M | $36.4M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-6.0M | $-18.2M |
| Free Cash FlowOCF − Capex | — | $-19.8M |
| FCF MarginFCF / Revenue | — | -4982.2% |
| Capex IntensityCapex / Revenue | — | 406.5% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-33.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-6.0M | — | ||
| Q3 25 | $-10.8M | — | ||
| Q2 25 | $-8.3M | $-18.2M | ||
| Q1 25 | $-12.8M | $-4.3M | ||
| Q4 24 | $-10.3M | $-4.6M | ||
| Q3 24 | $-10.5M | $-4.1M | ||
| Q2 24 | $-9.2M | $-18.0M | ||
| Q1 24 | $-7.7M | $-4.2M |
| Q4 25 | — | — | ||
| Q3 25 | $-10.9M | — | ||
| Q2 25 | — | $-19.8M | ||
| Q1 25 | — | $-4.9M | ||
| Q4 24 | — | $-4.7M | ||
| Q3 24 | — | $-4.3M | ||
| Q2 24 | — | $-18.3M | ||
| Q1 24 | $-7.8M | $-4.3M |
| Q4 25 | — | — | ||
| Q3 25 | -9043.3% | — | ||
| Q2 25 | — | -4982.2% | ||
| Q1 25 | — | -1142.9% | ||
| Q4 24 | — | -2562.2% | ||
| Q3 24 | — | -1310.4% | ||
| Q2 24 | — | -19108.3% | ||
| Q1 24 | -3814.6% | -6043.7% |
| Q4 25 | — | — | ||
| Q3 25 | 15.0% | — | ||
| Q2 25 | — | 406.5% | ||
| Q1 25 | — | 135.1% | ||
| Q4 24 | 0.0% | 60.5% | ||
| Q3 24 | 0.0% | 63.8% | ||
| Q2 24 | 0.0% | 336.5% | ||
| Q1 24 | 39.0% | 125.4% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
